Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 11 September 2020, 09:41 HKT/SGT
Share:
    

Source: Eisai
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2020

TOKYO, Sept 11, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that a series of abstracts will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19 to 21, 2020. The abstracts highlight updates regarding Eisai's in-house discovered LENVIMA (lenvatinib mesylate, the orally available kinase inhibitor, "lenvatinib"), Halaven (eribulin mesylate, halichondrin class microtubule dynamics inhibitor, "eribulin") and its liposomal formulation.

There will be two oral presentations regarding the combination therapy of lenvatinib and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside of the United States and Canada)'s anti-PD-1 antibody, KEYTRUDA (pembrolizumab). Both of these presentations have been selected as Late-Breaking Abstracts. The interim results of the phase 2 study (LEAP-004) in advanced melanoma which had been treated with an anti-PD-1 or PD-L1 antibody (Abstract No: LBA44), as well as the interim results of the basket-type phase 2 study (LEAP-005) for 6 types (triple-negative breast cancer, ovarian cancer, gastric cancer, colorectal cancer, glioblastoma, and biliary tract cancer) of previously treated, advanced solid tumors (Abstract No: LBA41) will be presented.

There will also be an e-poster presentation (Abstract No: 346P) on the expansion cohort of HER2-negative breast cancer in a phase 1 study evaluating the eribulin liposomal formulation (E7389-LF) which aims to realize the efficient delivery to tumors.

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.


About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Sept 11, 2020 09:41 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Sept 18, 2020 10:29 HKT/SGT
Eisai Presents Latest Data of Phase I Clinical Trial on Liposomal Formulation of Anti-Cancer Agent Halaven (Eribulin) at ESMO Virtual Congress 2020
Sept 17, 2020 08:59 HKT/SGT
Eisai Establishes Pharma Sales Subsidiary in Vietnam
Sept 7, 2020 08:02 HKT/SGT
Eisai to Take over Manufacturing and Marketing Approval for Equfina 50mg Tablets (Safinamide Mesilate) in Japan from Meiji Seika Pharma
Aug 25, 2020 11:55 HKT/SGT
Eisai to Launch Sahne Medical Spray and Sahne Medical Cream
Aug 25, 2020 09:30 HKT/SGT
Eisai to Present Latest Data of Lemborexant at 34th Annual Sleep Meeting (SLEEP2020)
July 31, 2020 08:31 HKT/SGT
Eisai: Application for Additional Indication of Anti Cancer Agent Lenvima for Unresectable Thymic Carcinoma Submitted in Japan
July 22, 2020 16:04 HKT/SGT
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the Alzheimer's Association International Conference (AAIC) 2020
July 20, 2020 11:36 HKT/SGT
Eisai: Smartphone App for Vital Signs Measurement of Patients With the Novel Coronavirus Infection Experimental Study Project Adopted as AMED Project
July 14, 2020 08:20 HKT/SGT
Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease
July 13, 2020 10:47 HKT/SGT
Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded
More news >>
 News Alerts
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: